A new inter partes review has been filed at the Patent Trial and Appeal Board against ResMed Corp., opening another front in the increasingly important fight over respiratory and sleep-therapy technology. The petition, docketed as IPR2026-00341 and filed June 12, 2026, places at issue the validity of a ResMed patent before the PTAB, where petitioners can seek cancellation of issued patent claims based on prior art patents and printed publications.

At this early stage, the publicly available docket information identifies the proceeding as Resmed Corp., but does not yet provide the full set of petition details typically most relevant to practitioners, including the patent number, the petitioner’s identity, and the specific prior-art combinations asserted. As the petition, exhibits, and any preliminary response are added to the docket, those filings should clarify exactly which claims are under challenge and whether the asserted grounds focus on anticipation under 35 U.S.C. § 102, obviousness under 35 U.S.C. § 103, or both.

Even with limited initial metadata, this filing is notable. ResMed is a major player in connected respiratory care, PAP devices, masks, and digital health platforms. PTAB petitions involving companies in this space often have significance beyond a single patent, especially where the challenged claims may relate to core device functionality, patient monitoring, data transmission, or comfort and compliance features. For in-house IP counsel and patent prosecutors, the case may offer insight into how competitors are targeting claim scope in a crowded and highly technical medical-device landscape.

Patent litigators should also watch for whether this IPR runs alongside district court litigation, ITC activity, or licensing disputes. As in many high-value medical technology matters, the PTAB can become a strategic venue for testing patent strength early and relatively efficiently. Institution decisions, claim-construction positions, and expert declarations in cases like this can shape leverage in parallel disputes and influence broader portfolio strategy.

Practitioners will want to monitor several key developments: identification of the challenged patent, the precise claims at issue, whether the Board institutes trial, and how the parties frame any real-party-in-interest or discretionary-denial issues. Depending on the petition’s content, this proceeding could become a useful data point on PTAB treatment of digital-health and respiratory-device prior art.

View full case on Docket Alarm